CDw17 antibody
-
- Target
- CDw17
- Reactivity
- Human
-
Host
- Mouse
-
Clonality
- Monoclonal
-
Conjugate
- Un-conjugated
-
Application
- Flow Cytometry (FACS), Immunofluorescence (IF)
- Immunogen
- β-2 Microglobulin associated proteins from a detergent lysate of human PBL
- Clone
- HuLy-m13
- Isotype
- IgM kappa
-
-
- Application Notes
-
Positive Control: Human PBL. Tonsil.
Known Application: Flow Cytometry (0.5-1 μg/million cells), Immunofluorescence (0.5-1 μg/mL), Optimal dilution for a specific application should be determined.
- Restrictions
- For Research Use only
-
- Concentration
- 200 μg/mL
- Buffer
- 10 mM PBS with 0.05 % BSA & 0.05 % azide.
- Preservative
- Sodium azide
- Precaution of Use
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- Storage
- 4 °C,-80 °C
- Storage Comment
- Antibody with azide - store at 2 to 8°C. Antibody without azide - store at -20 to -80°C. Antibody is stable for 24 months. Non-hazardous. No MSDS required.
- Expiry Date
- 24 months
-
- Target
- CDw17
- Background
- CD17 is an intermediate glycosphingolipid from the metabolism of higher gangliosides that localizes to sphingolipid-sterol rafts. CD17 is detectable in monocytes, granulocytes, basophils, platelets, a subset of peripheral B cells (CD19+) and tonsil dendritic cells. It is rapidly down regulated on activated granulocytes and is upregulated on IL-2 activated T lymphocytes. CD17 binds to bacteria and may function in phagocytosis. VEGF-treated endothelial cells can produce CD17, which can then mediate signaling toward PECAM-1 expression and angiogenesis. Tumor necrosis factor )-induced astrogliosis (astrocyte proliferation and glial fibrillary acidic protein (GFAP) upregulation) in response to neuro-inflammation (i.e. spinal cord injury) causes an increase in intracellular levels of CD17. Aberrant levels of glycosphingolipids are a feature of cancer cells and may influence integrin clustering and internalization.
-